Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) has received U.S. FDA approval for SKYRIZI® (risankizumab-rzaa) for the treatment of moderately to severely active ulcerative colitis. This approval is based on positive results from two Phase 3 clinical trials: a 12-week induction study (INSPIRE) and a 52-week maintenance study (COMMAND). SKYRIZI is now the first IL-23 specific inhibitor approved for treating both moderate to severe ulcerative colitis and Crohn's disease. The treatment showed significant clinical and endoscopic improvements. The dosing regimen includes an initial 12-week induction followed by maintenance therapy. This approval broadens AbbVie’s portfolio in inflammatory bowel disease, demonstrating its commitment to addressing the needs of over 1 million people affected by ulcerative colitis in the U.S. The drug is available with patient support programs to reduce out-of-pocket costs for eligible patients.
AbbVie (NYSE: ABBV) advises shareholders to reject Tutanota 's unsolicited "mini-tender" offer to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share. The offer, dated May 28, 2024, is conditioned on the stock's market price exceeding the offer price before the offer's expiration on June 28, 2024. AbbVie warns that accepting the offer could result in selling shares at below-market prices and highlights the lack of investor protections in mini-tender offers, as noted by the SEC. Shareholders who have already tendered their shares can withdraw them by following the instructions in Tutanota's offer documents. AbbVie emphasizes the importance of consulting financial advisors and reviewing current stock quotes before making any decisions.
AbbVie and FutureGen Biopharmaceutical announced a global license agreement to develop FG-M701, a next-generation TL1A antibody for treating inflammatory bowel disease (IBD). FG-M701 is in preclinical development and aims to offer improved efficacy and less frequent dosing compared to first-generation therapies. AbbVie will receive exclusive rights to develop, manufacture, and commercialize FG-M701. FutureGen will receive $150 million in upfront and near-term milestone payments, with the potential for up to $1.56 billion in additional payments and tiered royalties up to low-double digits on net sales. The collaboration aims to advance treatment options for patients with IBD.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the 2024 recipients of the BOTOX® Cosmetic Women Entrepreneur Grant. Twenty women entrepreneurs will receive $25,000 each, mentorship, and community support. This year's program saw nearly 11,000 applicants, almost double from 2023. The grant aims to address funding disparities, particularly for BIPOC women, and includes enhanced coaching and networking opportunities. The recipients' support began with a bootcamp in New York City and will continue with a ten-week Crowdfunding Coaching Accelerator program. This initiative highlights AbbVie's commitment to empowering women entrepreneurs.
AbbVie (NYSE: ABBV) has announced positive topline results from its Phase 2 PICCOLO trial of mirvetuximab soravtansine (ELAHERE®) for folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The trial met its primary endpoint, achieving an objective response rate (ORR) of 51.9% (95% CI 40.4 – 63.3%).
Additionally, the median duration of response (DOR), a key secondary endpoint, was reported at 8.25 months. The safety profile was consistent with previous studies, with no new safety concerns identified. Full data will be presented at an upcoming medical meeting.
Dr. Angeles Alvarez Secord from the Duke Cancer Institute highlighted the need for new treatment options in PSOC, emphasizing the trial's significance for this patient group.
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), celebrates 25 years of SkinMedica®, its premium skincare line. From June 1 to June 25, 2024, Allē Members purchasing SkinMedica® products can earn double points and enter a sweepstakes to win $5,000. Since its inception in 1999, SkinMedica® has been a leader in science-backed skincare, renowned for products like the TNS Recovery Complex® and TNS® Advanced+ Serum. The brand was co-founded by dermatologist Dr. Kimberly Butterwick, who emphasizes its blend of science and luxury. As SkinMedica® commemorates this milestone, followers are encouraged to engage on Instagram with the hashtag #25YearsOfSkinMedica.
AbbVie has launched the Migraine Career Catalyst Award™, a unique contest aimed at supporting the career aspirations of individuals living with migraine. The contest offers 20 winners up to $2,500 each, which can be used for career counseling, professional development, and networking opportunities. The initiative underscores AbbVie's commitment to addressing the impact of migraine in the workplace. The submission period is open until September 3, 2024, with winners announced on November 15, 2024. This contest is open to legal residents of the U.S., D.C., and Puerto Rico who are 18 or older.
AbbVie (NYSE: ABBV) announced the commencement of its CERVINO Phase 3 trial, evaluating the efficacy, safety, and tolerability of its investigational drug, ABBV-383, for treating relapsed/refractory multiple myeloma (r/r MM).
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager with distinctive bivalent BCMA-binding domains and a low-affinity CD3 binding domain, designed for high BCMA-avidity. The trial involves a multicenter, randomized, open-label study comparing ABBV-383 monotherapy to standard available therapies (SATs) in patients who have undergone at least two prior treatment lines.
Multiple myeloma is a significant global health concern, affecting 176,000 new patients and causing 117,000 deaths in 2020. The study aims to offer a novel treatment option with a monthly dosing regimen, potentially simplifying treatment for both physicians and patients.
AbbVie announced that RINVOQ (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA), who have not responded well to TNF blockers.
This marks the first pediatric indication for RINVOQ, which is now approved for eight immune-mediated inflammatory diseases. A new weight-based oral solution, RINVOQ LQ, is also available.
The approval is based on data from adult and pediatric studies showing comparable plasma exposures and safety profiles in children and adults.
RINVOQ may cause serious side effects, including infections, cancer, and cardiovascular issues.
Allergan Aesthetics, a company under AbbVie (NYSE: ABBV), has introduced a new Refer a Friend feature for its Allē Loyalty Rewards Program. Starting June 4, 2024, Allē Members can invite friends and family to join, allowing both parties to earn up to $50 in savings on Allergan Aesthetics products and treatments such as BOTOX® Cosmetic, JUVÉDERM® Fillers, and CoolSculpting®. Members can refer up to five new users per offer period and receive $10 per referral. With over 7 million members, Allē aims to educate consumers about aesthetic treatments while offering rewards.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
